Wall Street analysts expect that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will announce earnings per share (EPS) of ($0.38) for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.45). Tetraphase Pharmaceuticals posted earnings per share of ($0.18) during the same quarter last year, which indicates a negative year-over-year growth rate of 111.1%. The company is scheduled to report its next quarterly earnings results on Thursday, August 1st.
On average, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($1.50) per share for the current fiscal year, with EPS estimates ranging from ($1.78) to ($1.29). For the next financial year, analysts anticipate that the business will report earnings of ($1.13) per share, with EPS estimates ranging from ($1.68) to ($0.81). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.03. Tetraphase Pharmaceuticals had a negative return on equity of 80.01% and a negative net margin of 383.19%. The company had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.93 million.
Tetraphase Pharmaceuticals stock traded down $0.01 during midday trading on Thursday, reaching $0.73. The company’s stock had a trading volume of 446,035 shares, compared to its average volume of 608,399. Tetraphase Pharmaceuticals has a 52 week low of $0.71 and a 52 week high of $4.49. The company has a quick ratio of 7.10, a current ratio of 7.28 and a debt-to-equity ratio of 0.53. The stock has a market cap of $41.78 million, a PE ratio of -0.53 and a beta of 2.90.
Institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its position in Tetraphase Pharmaceuticals by 890.0% in the fourth quarter. Deutsche Bank AG now owns 1,040,447 shares of the biopharmaceutical company’s stock valued at $1,174,000 after acquiring an additional 935,349 shares during the last quarter. 683 Capital Management LLC grew its position in Tetraphase Pharmaceuticals by 10.6% in the fourth quarter. 683 Capital Management LLC now owns 790,571 shares of the biopharmaceutical company’s stock valued at $893,000 after acquiring an additional 75,474 shares during the last quarter. Two Sigma Advisers LP grew its position in Tetraphase Pharmaceuticals by 50.2% in the fourth quarter. Two Sigma Advisers LP now owns 221,000 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 73,900 shares during the last quarter. SG Americas Securities LLC bought a new position in Tetraphase Pharmaceuticals in the fourth quarter valued at about $69,000. Finally, Rhumbline Advisers grew its holdings in shares of Tetraphase Pharmaceuticals by 40.6% during the fourth quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 21,089 shares during the last quarter. Hedge funds and other institutional investors own 38.67% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Featured Story: What does a bar chart display?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.